Melbourne, June 20, 2026, 05:04 AEST
- Pro Medicus finished Friday up 3.1% and added 5.4% for the week, ending at A$172.80.
- About 1.33 million shares traded ahead of the company’s removal from the S&P/ASX 50 on Monday.
- The stock managed gains Friday, going against a 0.9% drop in the S&P/ASX 200. Large miners were weaker and pulled the index down.
Pro Medicus Ltd ended Friday at A$172.80, adding A$5.19. Buyers came back to the medical-imaging software stock ahead of a benchmark index move. The Australian market is now shut for the weekend.
Heavy trading, not the share price move itself, stood out. Nearly 1.3 million shares were traded—about four times what the stock usually sees—on the last day before Pro Medicus exits the S&P/ASX 50. ALS Ltd takes the spot when the index update kicks in before Monday’s open.
An index rebalance is when the members of a benchmark are shuffled. Funds that follow the benchmark often sell shares of any company that’s dropped and buy the new names added. These trades are one-offs and don’t always point to a shift in the actual business.
Pro Medicus shares climbed even as the expected mechanical selling took place. The day’s sharp turnover looks tied to the rebalance, as the timing points to that as the likely cause. Public trading data doesn’t show who was buying or selling. The company didn’t release anything new on Friday. Its latest listed update was the June 5 index notice.
Pro Medicus shares climbed from A$164 last week as the S&P/ASX 200 edged up just 0.3% between Friday closes. But the stock is still trading about 49% under its July 2025 high of A$336 and sits 38% lower over the past year. The bounce hasn’t brought it close to its record yet.
Contract wins have given Pro Medicus a lift. The company announced A$60 million in new and extended deals from the US in early June, with Allegheny Health Network, TidalHealth, and Ohio State University Wexner Medical Center all signing on. The Ohio State deal pushed total renewals for fiscal 2026 up to A$141 million. “This contract brings our total renewals for the financial year to A$141M,” Chief Executive Sam Hupert said. ASX Announcements
RBC Capital Markets analyst Jackson Lee said the renewals pointed to customers expanding usage instead of cutting deal lengths, pushing back on worries that hospitals were after shorter commitments to weigh artificial-intelligence options. RBC kept its “sector perform” call and A$195 price target after the deals in early June. Moomoo
Monday will show if the first day outside the ASX 50 sees more passive outflows or if most of that selling already hit at Friday’s close. Past the technical moves, management is still looking for a lift in transaction volumes in the first half of fiscal 2027 as new hospital installs start adding revenue.
Valuation and competition are still the big risks here. Morningstar analyst Brian Han sticks to his A$54 fair-value call and keeps the stock at high uncertainty. He says the main market might be smaller than investors think, while rivals Sectra and AGFA HealthCare are picking up speed. A stall in renewals, a fading tech edge, or new AI-disruption worries could set off another heavy de-rating, even if recent index selling turns out short-lived.
